FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ute Berger

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Drug Resistance, Neoplasm

Genes & Molecular Sequences

Genes, abl

Co-author Network

Publications

TOP 3
Rüdiger Hehlmann; Ute Berger; Markus Pfirrmann; Hermann Heimpel; Andreas Hochhaus; Joerg Hasford; Hans-Jochem Kolb; Tanja Lahaye; Ole Maywald; Andreas Reiter; Dieter K Hossfeld; Christoph Huber; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler; Christoph Nerl; Max Solenthaler; Mariele E Goebeler; Martin Griesshammer; Thomas Fischer; Stephan Kremers; Hartmut Eimermacher; Michael Pfreundschuh; Wolf-Dietrich Hirschmann; Klaus Lechner; Barbara Wassmann; Christiane Falge; Hartmut H Kirchner; Alois Gratwohl
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Susanne Saussele; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla; Rüdiger Hehlmann
[Clinical research within the German competence net "acute and chronic leukemias"].
Ole Maywald; Markus Pfirrmann; Ute Berger; Lusine Breitscheidel; Alois Gratwohl; Hans-Jochem Kolb; D W Beelen; Andreas Tobler; Georgia Metzgeroth; S U Gnad; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann; Andreas Reiter
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ute Berger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Rüdiger Hehlmann; Ute Berger; Markus Pfirrmann; Hermann Heimpel; Andreas Hochhaus; Joerg Hasford; Hans-Jochem Kolb; Tanja Lahaye; Ole Maywald; Andreas Reiter; Dieter K Hossfeld; Christoph Huber; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler; Christoph Nerl; Max Solenthaler; Mariele E Goebeler; Martin Griesshammer; Thomas Fischer; Stephan Kremers; Hartmut Eimermacher; Michael Pfreundschuh; Wolf-Dietrich Hirschmann; Klaus Lechner; Barbara Wassmann; Christiane Falge; Hartmut H Kirchner; Alois Gratwohl
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood 2007;109(11):4686-92.
2006: Susanne Saussele; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla; Rüdiger Hehlmann
[Clinical research within the German competence net "acute and chronic leukemias"].
Medizinische Klinik (Munich, Germany : 1983) 2006;101(5):414-20.
2006: Ole Maywald; Markus Pfirrmann; Ute Berger; Lusine Breitscheidel; Alois Gratwohl; Hans-Jochem Kolb; D W Beelen; Andreas Tobler; Georgia Metzgeroth; S U Gnad; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann; Andreas Reiter
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
Leukemia 2006;20(3):477-84.
2005: Rüdiger Hehlmann; Ute Berger; Andreas Hochhaus
Chronic myeloid leukemia: a model for oncology.
Annals of hematology 2005;84(8):487-97.
2005: Ute Berger; Ole Maywald; Markus Pfirrmann; Tanja Lahaye; Andreas Hochhaus; Andreas Reiter; Joerg Hasford; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Rüdiger Hehlmann
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Leukemia 2005;19(6):984-9.
2005: Tanja Lahaye; Birte Riehm; Ute Berger; Peter Paschka; Martin C Müller; Sebastian Kreil; Kirsten Merx; Uwe Schwindel; Claudia Schoch; Rüdiger Hehlmann; Andreas Hochhaus
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Cancer 2005;103(8):1659-69.
2005: Andreas Reiter; Christoph Walz; Ann Watmore; Claudia Schoch; Ilona Blau; Brigitte Schlegelberger; Ute Berger; Nick Telford; Shilani Aruliah; John A Yin; Danny Vanstraelen; Helen F Barker; Peter C Taylor; Aisling O'Driscoll; Fabio Benedetti; Cornelia Rudolph; Hans-Jochem Kolb; Andreas Hochhaus; Rüdiger Hehlmann; Andrew Chase; Nicholas C P Cross
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Cancer research 2005;65(7):2662-7.
2004: Rüdiger Hehlmann; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla
[The competence network "acute and chronic leukemias"].
Deutsche medizinische Wochenschrift (1946) 2004;129(49):2660-5.
2004: Andreas Hochhaus; Ute Berger; Rüdiger Hehlmann
[Therapy of chronic myelogenous leukemia in 2004].
Deutsche medizinische Wochenschrift (1946) 2004;129(40):2122-7.
2004: Rüdiger Hehlmann; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Dieter Hoelzer; Nicola Gökbuget; Karl Uberla
[Clinical research in the "acute and chronic leukemias"competence network ].
Der Internist 2004;45(4):384-92.
2004: Ute Berger; Georg Engelich; Andreas Reiter; Andreas Hochhaus; Rüdiger Hehlmann
Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Annals of hematology 2004;83(4):258-64.
2004: Ute Berger; Rüdiger Hehlmann
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Der Internist 2004;45(1):102-3.
2003: Martin C Müller; Norbert Gattermann; Tanja Lahaye; Michael W N Deininger; A Berndt; Stefan Fruehauf; Andreas Neubauer; Thomas Fischer; Dieter K Hossfeld; Folker Schneller; S W Krause; Christoph Nerl; Herbert G Sayer; Oliver G Ottmann; C Waller; Walter Aulitzky; Philipp le Coutre; Mathias Freund; Kirsten Merx; Peter Paschka; Heiko König; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia 2003;17(12):2392-400.
2003: Ute Berger; Georg Engelich; Ole Maywald; Markus Pfirrmann; Andreas Hochhaus; Andreas Reiter; Georgia Metzgeroth; U Gnad; Joerg Hasford; Barbara Heinze; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Rüdiger Hehlmann
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Leukemia 2003;17(9):1820-6.
2003: Peter Paschka; Martin C Müller; Kirsten Merx; Sebastian Kreil; Claudia Schoch; Tanja Lahaye; Andreas Weisser; A Petzold; Heiko König; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Leukemia 2003;17(9):1687-94.
2003: Tim H Brummendorf; Inci Ersoz; Ulrike Hartmann; Stefan Balabanov; Holger Wolke; Peter Paschka; Tanja Lahaye; Birgit Berner; Kerol Bartolovic; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rüdiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Annals of the New York Academy of Sciences 2003;996():26-38.
2003: Tim H Brümmendorf; Inci Ersöz; Ulrike Hartmann; Kerol Bartolovic; Stefan Balabanov; Alexandra Wahl; Peter Paschka; Sebastian Kreil; Tanja Lahaye; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rüdiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Blood 2003;101(1):375-6.
2002: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Martin C Müller; Tanja Lahaye; B Hanfstein; Claudia Schoch; Nicholas C P Cross; Ute Berger; Harald Gschaidmeier; Brian J Druker; Rüdiger Hehlmann
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia 2002;16(11):2190-6.
2002: R Helmann; Ute Berger; Georg Engelich
[Imatinib combination therapies--the new CML Study 4].
Deutsche medizinische Wochenschrift (1946) 2002;127(42):224-6.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Georg Engelich; Tanja Lahaye; Sebastian Kreil; Kirsten Merx; Martin C Müller; Rüdiger Hehlmann
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Der Internist 2002;43(10):1228, 1231-8, 1241-4.
2002: Kirsten Merx; Martin C Müller; Sebastian Kreil; Tanja Lahaye; Peter Paschka; Claudia Schoch; Andreas Weisser; C Kuhn; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Leukemia 2002;16(9):1579-83.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Rüdiger Hehlmann
[Current pharmacotherapy of chronic myeloid leukemia].
Der Internist 2002;43(2):270-83.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Tanja Lahaye; Sebastian Kreil; Rüdiger Hehlmann
[Drug therapy of chronic myeloid leukemia].
Medizinische Klinik (Munich, Germany : 1983) 2002;97 Suppl 1():7-15.
2001: J de la Fuente; Kirsten Merx; E J Steer; M Müller; R M Szydlo; Ole Maywald; Ute Berger; Rüdiger Hehlmann; J M Goldman; N C Cross; J V Melo; Andreas Hochhaus
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.
Blood 2001;98(9):2879-80.
2001: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Tanja Lahaye; Ute Berger; Nicholas C P Cross; W Linkesch; Brian J Druker; Rüdiger Hehlmann; C Gambacorti- Passerini; G Corneo; M D'Incalci
Roots of clinical resistance to STI-571 cancer therapy.
Science (New York, N.Y.) 2001;293(5538):2163.
2001: Andreas Hochhaus; Tanja Lahaye; Sebastian Kreil; Ute Berger; Georgia Metzgeroth; Rüdiger Hehlmann
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology].
Onkologie 2001;24 Suppl 5():65-71.
2001: Andreas Reiter; Andreas Hochhaus; Ute Berger; C Kuhn; Rüdiger Hehlmann
AraC-based pharmacotherapy of chronic myeloid leukaemia.
Expert opinion on pharmacotherapy 2001;2(7):1129-35.
2000: Andreas Hochhaus; Andreas Weisser; Paul La Rosée; Michael Emig; Martin C Müller; Susanne Saussele; Andreas Reiter; C Kuhn; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross
Detection and quantification of residual disease in chronic myelogenous leukemia.
Leukemia 2000;14(6):998-1005.
2000: Eva Lengfelder; Ute Berger; Rüdiger Hehlmann
Interferon alpha in the treatment of polycythemia vera.
Annals of hematology 2000;79(3):103-9.
2000: Andreas Hochhaus; Andreas Reiter; Susanne Saussele; Anja Reichert; Michael Emig; J Kaeda; Beate Schultheis; Ute Berger; P C Shepherd; N C Allan; Rüdiger Hehlmann; J M Goldman; Nicholas C P Cross
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Blood 2000;95(1):62-6.
1999: Rüdiger Hehlmann; Andreas Hochhaus; Hans-Jochem Kolb; Joerg Hasford; Alois Gratwohl; Hermann Heimpel; Wolfgang Siegert; J Finke; Gerhard Ehninger; E Holler; Ute Berger; Markus Pfirrmann; A Muth; Axel Zander; A A Fauser; A Heyll; Christoph Nerl; Dieter K Hossfeld; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Blood 1999;94(11):3668-77.
1999: Michael Emig; Susanne Saussele; H Wittor; Andreas Weisser; Andreas Reiter; Andreas Willer; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Hochhaus
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Leukemia 1999;13(11):1825-32.
1998: Andreas Hochhaus; Ute Berger; A Krämer; Andreas Reiter; Wolfgang Seifarth; Andreas Willer; Rüdiger Hehlmann
Congress Report: XIX symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Mannheim/Heidelberg, Germany, July 13 - 18, 1997.
European journal of medical research 1998;3(4):216-22.
1998: Andreas Hochhaus; Ute Berger; A Krämer; Andreas Reiter; Wolfgang Seifarth; Andreas Willer; Rüdiger Hehlmann
XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, July 13-18 Mannheim/Heidelberg, Germany, 1997.
Journal of cancer research and clinical oncology 1998;124(3-4):220-30.
1997: Rüdiger Hehlmann; Andreas Willer; Hermann Heimpel; Joerg Hasford; Hans-Jochem Kolb; Hans Pralle; Dieter K Hossfeld; Wolfgang Queisser; Helmut Löffler; Andreas Hochhaus; Andreas Tobler; Eva Lengfelder; Ute Berger; Christine Leib-Mösch
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.
Leukemia 1997;11 Suppl 3():506-11.
1996: Andreas Hochhaus; A Reiter; Heyko Skladny; Junia V Melo; C Sick; Ute Berger; J Q Guo; R B Arlinghaus; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Blood 1996;88(6):2236-40.
1996: Rüdiger Hehlmann; Hermann Heimpel; Dieter K Hossfeld; Joerg Hasford; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Hochhaus; A Tichelli; W Fett; Norbert Schmitz; A Reiter; Martin Griesshammer; W Pfeifer; M Bümler; T Kamp; Andreas Tobler; Hartmut Eimermacher; R Kuse; Ute Berger; H Ansari
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Bone marrow transplantation 1996;17 Suppl 3():S21-4.